share_log

8-K: Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

8-K: Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

8-K：Applied DNA 公佈2024財年第三季度財務業績
美股SEC公告 ·  2024/08/09 04:21

Moomoo AI 已提取核心訊息

Applied DNA Sciences reported Q3 FY2024 results with total revenues of $798,000, down from $2.9 million in Q3 FY2023, primarily due to the conclusion of a COVID-19 testing contract. The company posted a net income of $1.85 million, compared to a net loss of $3.11 million in the same period last year, largely due to a $5.16 million unrealized gain on warrant liabilities.Applied DNA's GMP facility for Linea IVT template manufacture remains on schedule for FY24 year-end launch, with an initial annual capacity to produce up to 15 million mRNA vaccine doses. The company secured two customer approvals as a GMP vendor and expects production runs to begin in early CY25. In the MDx Testing Services segment, Applied DNA established a potential $25 million annual revenue opportunity for its TR8 PGx testing service.Cash and cash equivalents stood at $10.4 million as of June 30, 2024, bolstered by a $10.5 million net proceeds from a public offering. The company anticipates key inflection points across all three business segments to drive total revenue growth year-over-year starting in the first half of fiscal 2025.
Applied DNA Sciences reported Q3 FY2024 results with total revenues of $798,000, down from $2.9 million in Q3 FY2023, primarily due to the conclusion of a COVID-19 testing contract. The company posted a net income of $1.85 million, compared to a net loss of $3.11 million in the same period last year, largely due to a $5.16 million unrealized gain on warrant liabilities.Applied DNA's GMP facility for Linea IVT template manufacture remains on schedule for FY24 year-end launch, with an initial annual capacity to produce up to 15 million mRNA vaccine doses. The company secured two customer approvals as a GMP vendor and expects production runs to begin in early CY25. In the MDx Testing Services segment, Applied DNA established a potential $25 million annual revenue opportunity for its TR8 PGx testing service.Cash and cash equivalents stood at $10.4 million as of June 30, 2024, bolstered by a $10.5 million net proceeds from a public offering. The company anticipates key inflection points across all three business segments to drive total revenue growth year-over-year starting in the first half of fiscal 2025.
Applied DNA Sciences公佈了2024財年第三季度的業績，總營業收入爲798,000美元，低於2023財年第三季度的290萬美元，主要由於COVID-19萬億合同的結束。該公司凈利潤爲185萬美元，較去年同期的淨虧損311萬美元大幅改善，這主要得益於對認股權利義務的516萬美元未實現收益。Applied DNA的GMP設施在Linea IVt模板製造方面按計劃推進，預計在2024財年末啓動，初始年產能可生產高達1500萬劑mRNA生物-疫苗。該公司獲得了兩個客戶作爲GMP供應商的批准，預計生產將在2025年初開始。在MDx檢測服務領域，Applied DNA爲其TR8 PGx檢測服務建立了一個2500萬美元的潛在年度營業收入機會。截至2024年6月30日，現金及現金等價物爲1040萬美元，得益於公共發行的1050萬美元淨收益。該公司預計將在所有業務板塊實現關鍵轉折點，將推動2025財年上半年總營業收入的同比增長。
Applied DNA Sciences公佈了2024財年第三季度的業績，總營業收入爲798,000美元，低於2023財年第三季度的290萬美元，主要由於COVID-19萬億合同的結束。該公司凈利潤爲185萬美元，較去年同期的淨虧損311萬美元大幅改善，這主要得益於對認股權利義務的516萬美元未實現收益。Applied DNA的GMP設施在Linea IVt模板製造方面按計劃推進，預計在2024財年末啓動，初始年產能可生產高達1500萬劑mRNA生物-疫苗。該公司獲得了兩個客戶作爲GMP供應商的批准，預計生產將在2025年初開始。在MDx檢測服務領域，Applied DNA爲其TR8 PGx檢測服務建立了一個2500萬美元的潛在年度營業收入機會。截至2024年6月30日，現金及現金等價物爲1040萬美元，得益於公共發行的1050萬美元淨收益。該公司預計將在所有業務板塊實現關鍵轉折點，將推動2025財年上半年總營業收入的同比增長。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Exagen
    XGN
    -- 3.990
    Atlantic International
    ATLN
    -- 5.650
    Neuronetics
    STIM
    -- 2.460
    XWELL Inc
    XWEL
    -- 1.2500
    Precipio
    PRPO
    -- 6.5100

    解鎖榜首股票

    熱門討論
    特朗普2.0時代倒計時！全球股市的下一個風口？
    🎙️️討論： 1. 加密貨幣政策能否利好crypto? 2. 關稅政策能否利好中概等海外資產？ 展开
    特朗普2.0機會預告：在總統上任之前猜測市場贏家！